Single-arm P1/2 study | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma.

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentaries on Twitter

In a phase I trial of the novel cereblon E3 ligase modulator iberdomide+dexamethasone in pts with RRMM, SAEs occurred in 53%, with one treatment-related death. The ORRs were 32% in the dose-escalation (n=90) & 26% in the dose-expansion (n=107) cohorts: https://t.co/rfRCUfCABb

— NatureRevClinOncol (@NatRevClinOncol) October 14, 2022

NEW research: iberdomide plus dexa was generally safe and showed meaningful clinical activity in heavily pretreated patients with multiple myeloma, including in disease that was refractory to immunomodulatory drugs in this ph 1-2 trial #mmsmhttps://t.co/x1ta31eKtk pic.twitter.com/2URVIoFIAi

— The Lancet Haematology (@TheLancetHaem) October 7, 2022